Details of Disease

General Information of Disease (ID: DISC1H1Z)

Disease Name	Kaposi sarcoma
Synonyms	human herpesvirus 8; non AIDS related Kaposi sarcoma; KSHV; Mediterranean Kaposi sarcoma; HHV8; Kaposi sarcoma herpesvirus; African lymphadenopathic Kaposi's sarcoma; Kaposi's sarcoma-associated herpesvirus (KSHV); conjunctival Kaposi's sarcoma; Kaposi's sarcoma of penis; pulmonary Kaposi's sarcoma; soft tissue Kaposi's sarcoma; Kaposi's sarcoma of central nervous system; gastric Kaposi's sarcoma; anal Kaposi's sarcoma; Kaposi's sarcoma of gastrointestinal sites; Kaposi's sarcoma of the gallbladder; cardiac Kaposi's sarcoma; Kaposi's sarcoma of anus; Kaposi's sarcoma of skin; Kaposi's sarcoma of lymph nodes; Kaposi's sarcoma of the CNS; prostate Kaposi's sarcoma; multiple hemorrhagic sarcoma; Kaposi's sarcoma of oesophagus; lymphadenopathic Kaposi's sarcoma; lymph node Kaposi's sarcoma; palate Kaposi's sarcoma; Kaposi's sarcoma of the prostate; Kaposi's sarcoma, skin; corneal Kaposi's sarcoma; gallbladder Kaposi's sarcoma; penis Kaposi's sarcoma; Kaposi's sarcoma, lung; intestinal Kaposi's sarcoma; cutaneous Kaposi's sarcoma; Kaposi's sarcoma of esophagus; central nervous system Kaposi's sarcoma; esophageal Kaposi's sarcoma; Kaposi's sarcoma of heart; Kaposi's sarcoma of cornea; Kaposi's sarcoma (disease); Kaposi's sarcoma; Kaposi's sarcoma of lung; Kaposi sarcoma; Kaposi's sarcoma of soft tissues; Kaposi's sarcoma of palate; Kaposi's sarcoma of soft tissue; KS; Kaposi's sarcoma of conjunctiva
Disease Class	2B57: Kaposi sarcoma
Definition	A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).
Disease Hierarchy	DISIYS9W: Angiosarcoma DISSU8N1: Human herpesvirus 8-related tumor DISFYSIV: Virus infection DISC1H1Z: Kaposi sarcoma
ICD Code	ICD-11 ICD-11: 2B57 ICD-9 ICD-9: 176 Expand ICD-11 'XH36A5 Expand ICD-9 176
Disease Identifiers	MONDO ID MONDO_0005055 MESH ID D012514 UMLS CUI C0036220 MedGen ID 11321 HPO ID HP:0100726 Orphanet ID 33276 SNOMED CT ID 109385007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alitretinoin	DMME8LH	Approved	Small molecular drug	[1]
Daunorubicin	DMQUSBT	Approved	Small molecular drug	[2]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[3]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[4]
Vinblastine	DM5TVS3	Approved	Small molecular drug	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SEphB4-HSA	DMD8RU0	Phase 2	Recombinant protein	[6]
Veglin	DM931G7	Phase 1	NA	[7]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS 275291	DMKSFPE	Discontinued in Phase 3	Small molecular drug	[8]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MAb173	DM5IMAU	Preclinical	Antibody	[9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 56 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BUB1	TT78309	Limited	Biomarker	[10]
CDK6	TTO0FDJ	Limited	Biomarker	[11]
DLL4	TTV23LH	Limited	Altered Expression	[12]
FGF4	TTCEKVZ	Limited	Altered Expression	[13]
GADD45B	TTMDW9L	Limited	Biomarker	[14]
KIR2DL2	TTU0P73	Limited	Genetic Variation	[15]
SERPINH1	TTPSWQG	Limited	Biomarker	[16]
SHCBP1	TTZ9WGL	Limited	Altered Expression	[17]
SLC22A2	TT0XOJN	Limited	Altered Expression	[18]
SLC7A11	TTBZMIO	Limited	Genetic Variation	[19]
SSRP1	TTETDKQ	Limited	Biomarker	[20]
SUV39H1	TTUWQTK	Limited	Biomarker	[21]
TAOK3	TTO7L0V	Limited	Altered Expression	[22]
CACNA1G	TT729IR	Disputed	Genetic Variation	[23]
CERK	TT9XRNV	Disputed	Altered Expression	[24]
EGFL7	TT7WD0H	Disputed	Altered Expression	[25]
EPHA7	TTAHTVG	Disputed	Biomarker	[26]
S1PR3	TTDYP7I	Disputed	Altered Expression	[24]
ACKR3	TTRQJTC	Strong	Biomarker	[27]
ADRA1A	TTNGILX	Strong	Biomarker	[27]
ADRA2B	TTWM4TY	Strong	Biomarker	[27]
ANGPT2	TTKLQTJ	Strong	Altered Expression	[28]
ANGPTL4	TTWALY5	Strong	Biomarker	[29]
BCL6	TTC9YX5	Strong	Altered Expression	[30]
BRS3	TTKYEPM	Strong	Biomarker	[27]
CD86	TT53XHB	Strong	Biomarker	[31]
CXCR2	TT30C9G	Strong	Altered Expression	[32]
CXCR6	TT2BVUA	Strong	Biomarker	[27]
EDNRA	TTKRD0G	Strong	Biomarker	[27]
EPHA1	TTLFZVU	Strong	Altered Expression	[33]
EPHA2	TTRJB2G	Strong	Biomarker	[34]
EPHB4	TTI4ZX2	Strong	Biomarker	[33]
F13A1	TTXI2RA	Strong	Altered Expression	[35]
FLT4	TTDCBX5	Strong	Altered Expression	[36]
GPRC6A	TTI1PRE	Strong	Biomarker	[37]
IL6	TTT1V78	Strong	Biomarker	[38]
IRF3	TTYR7OH	Strong	Biomarker	[39]
ITGB3	TTJA1ZO	Strong	Biomarker	[38]
LPAR2	TTB7Y8I	Strong	Biomarker	[27]
LPAR3	TTE2YJR	Strong	Biomarker	[37]
LYVE1	TTG8DNU	Strong	Altered Expression	[36]
MAP4K4	TT6NI13	Strong	Biomarker	[40]
MRGPRX1	TTIX6PK	Strong	Biomarker	[37]
OSM	TTIVXSE	Strong	Biomarker	[41]
OXER1	TT7WBSV	Strong	Biomarker	[37]
PCNA	TTLG1PD	Strong	Biomarker	[42]
RBP4	TT0C8BY	Strong	Biomarker	[43]
RBPJ	TT72D4Z	Strong	Biomarker	[44]
RENBP	TTZCG0Q	Strong	Biomarker	[43]
SLK	TT8K4DE	Strong	Biomarker	[45]
SSTR4	TTAE1BR	Strong	Biomarker	[27]
STAT6	TTWOE1T	Strong	Biomarker	[46]
TRIM28	TTQ2BKV	Strong	Biomarker	[47]
TYRO3	TTIEMFN	Strong	Biomarker	[48]
USP7	TTXU3EQ	Strong	Biomarker	[49]
EPHA4	TTG84D3	Definitive	Biomarker	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 56 DTT(s)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NDUFS7	DEIW03B	Limited	Genetic Variation	[51]
UBASH3B	DE10BJ5	Disputed	Genetic Variation	[52]
------------------------------------------------------------------------------------

This Disease Is Related to 88 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARC	OTN2QQPG	Limited	Biomarker	[53]
ARID3B	OTUP9MS4	Limited	Biomarker	[54]
CGAS	OTJYIXNB	Limited	Biomarker	[55]
CLDN2	OTRF3D6Y	Limited	Altered Expression	[56]
CTTNBP2	OT4CL1EW	Limited	Biomarker	[57]
FERMT1	OT626PBA	Limited	Genetic Variation	[58]
FGF5	OTQXGHBY	Limited	Altered Expression	[59]
HLA-C	OTV38BUJ	Limited	Biomarker	[60]
IRF2	OTAZRUW3	Limited	Altered Expression	[61]
KIR3DS1	OTJWIO4T	Limited	Biomarker	[62]
LRIT1	OTNEQPMZ	Limited	Altered Expression	[17]
LRPAP1	OT6DVD2Q	Limited	Altered Expression	[63]
MNDA	OTCTKR47	Limited	Biomarker	[64]
MT3	OTVCZ7HI	Limited	Biomarker	[65]
OR10A4	OTYYB8SY	Limited	Genetic Variation	[66]
PF4V1	OT2CXM6L	Limited	Biomarker	[67]
PIK3C2A	OTFBU4GD	Limited	Biomarker	[68]
PIK3R2	OTZSUQK5	Limited	Biomarker	[69]
PLVAP	OTAQGWYA	Limited	Biomarker	[16]
POU2AF1	OTOO6WHL	Limited	Altered Expression	[18]
POU2F2	OTPV0J0C	Limited	Altered Expression	[18]
PWWP3A	OTXQVL4U	Limited	Altered Expression	[70]
RAD50	OTYMU9G1	Limited	Biomarker	[71]
RBM15	OT8ZPGWF	Limited	Altered Expression	[72]
RCAN1	OT1MVXC7	Limited	Altered Expression	[73]
RECQL	OTPCH3JH	Limited	Genetic Variation	[74]
RNASE1	OTKZ7CO9	Limited	Biomarker	[75]
RNASE2	OT8Z4FNE	Limited	Biomarker	[76]
RREB1	OT62460U	Limited	Biomarker	[77]
SEMA7A	OT0ZJK64	Limited	Genetic Variation	[78]
SUMO2	OT1Y5IKN	Limited	Biomarker	[79]
SUMO3	OTTUJQJ1	Limited	Biomarker	[79]
TAT	OT2CJ91O	Limited	Biomarker	[80]
TCHP	OTVDMHSY	Limited	Posttranslational Modification	[81]
TESC	OTI8C76M	Limited	Altered Expression	[82]
TNIP1	OTRAOTEW	Limited	Altered Expression	[83]
TNIP3	OTSAE5UE	Limited	Altered Expression	[83]
APBA1	OTUH9JPD	Disputed	Genetic Variation	[23]
APBA2	OTXD8ID1	Disputed	Genetic Variation	[23]
CASTOR1	OTYIH7WK	Disputed	Biomarker	[84]
CASTOR2	OT7G4ZYO	Disputed	Biomarker	[84]
CSHL1	OTQKU2F5	Disputed	Biomarker	[44]
DCP1A	OT3NCON3	Disputed	Biomarker	[85]
DDX6	OTKWXVDY	Disputed	Biomarker	[85]
IFI16	OT4SPU0U	Disputed	Biomarker	[86]
INHBB	OT2QLD11	Disputed	Genetic Variation	[23]
MPLKIP	OTV7BX5A	Disputed	Biomarker	[87]
NCOA2	OTMQFPBB	Disputed	Biomarker	[88]
NEUROG1	OTMJZP9G	Disputed	Genetic Variation	[23]
SCTR	OTC80IMR	Disputed	Biomarker	[23]
SMPX	OTLSHGBF	Disputed	Biomarker	[44]
SOCS6	OT2O5ZBK	Disputed	Biomarker	[89]
TNRC6A	OT493IOM	Disputed	Biomarker	[85]
ADA2	OTGCV24S	Strong	Biomarker	[90]
ANOS1	OTZJT4KN	Strong	Genetic Variation	[91]
CCL1	OT23NON8	Strong	Biomarker	[92]
CDKN3	OTBE3H07	Strong	Biomarker	[47]
CLIP1	OTTGAEJE	Strong	Biomarker	[93]
CLIP2	OTSCIQIY	Strong	Biomarker	[93]
CTCF	OT8ZB70U	Strong	Altered Expression	[94]
EFNB2	OT0DCUOM	Strong	Altered Expression	[33]
FAM107B	OT5RG4J0	Strong	Biomarker	[93]
FAM120C	OT2DH1SN	Strong	Altered Expression	[95]
FGF3	OT9PK2SI	Strong	Biomarker	[13]
FZD4	OTGLZIE0	Strong	Biomarker	[37]
GBP1	OTUM7RPJ	Strong	Biomarker	[96]
GPR151	OT7EACU6	Strong	Biomarker	[37]
GPR42	OTEB0ROY	Strong	Biomarker	[27]
IKBKE	OT5VYOSM	Strong	Biomarker	[97]
INTS2	OT2N5TCK	Strong	Biomarker	[13]
IRF4	OT1DHQ1P	Strong	Biomarker	[30]
IRF5	OT8SIIAP	Strong	Biomarker	[98]
IRF7	OTC1A2PQ	Strong	Biomarker	[99]
KRT15	OTS6WLF7	Strong	Altered Expression	[100]
LGR6	OTPZ1PWR	Strong	Biomarker	[37]
LRPPRC	OTXSK5LP	Strong	Biomarker	[101]
MIP	OTEBLU3E	Strong	Biomarker	[102]
MRGPRF	OT74OZ2Z	Strong	Genetic Variation	[103]
MRGPRX3	OTRKCCDS	Strong	Biomarker	[37]
MRGPRX4	OTOBHZVA	Strong	Biomarker	[37]
MZB1	OT071TET	Strong	Biomarker	[104]
PROX1	OT68R6IO	Strong	Biomarker	[105]
RBFOX2	OTXY1WVH	Strong	Genetic Variation	[103]
SIGLEC1	OTNWSQA9	Strong	Altered Expression	[106]
SUGP1	OT7W0EB8	Strong	Biomarker	[43]
SHFL	OTZ4771K	Definitive	Biomarker	[107]
SHISA8	OTI8Y0C1	Definitive	Genetic Variation	[108]
TRIM43	OT6SKRF0	Definitive	Biomarker	[109]
------------------------------------------------------------------------------------


⏷ Show the Full List of 88 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2645).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Doxorubicin FDA Label
4	Paclitaxel FDA Label
5	Vinblastine FDA Label
6	ClinicalTrials.gov (NCT03993106) A Study of sEphB4-HSA in Kaposi Sarcoma. U.S. National Institutes of Health.
7	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020056)
8	Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
9	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
10	Kaposi's sarcoma-associated herpesvirus-encoded LANA can induce chromosomal instability through targeted degradation of the mitotic checkpoint kinase Bub1.J Virol. 2014 Jul;88(13):7367-78. doi: 10.1128/JVI.00554-14. Epub 2014 Apr 16.
11	Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.PLoS Pathog. 2010 Mar 19;6(3):e1000818. doi: 10.1371/journal.ppat.1000818.
12	Latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus promotes angiogenesis through targeting notch signaling effector Hey1.Cancer Res. 2014 Apr 1;74(7):2026-37. doi: 10.1158/0008-5472.CAN-13-1467. Epub 2014 Feb 12.
13	FGF4 and INT2 oncogenes are amplified and expressed in Kaposi's sarcoma.Mod Pathol. 2000 Apr;13(4):433-7. doi: 10.1038/modpathol.3880074.
14	Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis.J Virol. 2017 Jan 18;91(3):e02045-16. doi: 10.1128/JVI.02045-16. Print 2017 Feb 1.
15	High prevalence of specific KIR types in patients with HHV-8 positive cutaneous vascular lesions: a possible predisposing factor?.Arch Dermatol Res. 2016 Jul;308(5):373-7. doi: 10.1007/s00403-016-1643-x. Epub 2016 Apr 8.
16	Human T-cell leukemia virus type I or a related retrovirus in patients with mycosis fungoides/Szary syndrome and Kaposi's sarcoma.Cancer Res. 1992 Aug 15;52(16):4391-5.
17	CD9 expression on lymphatic vessels in head and neck mucosa.Mod Pathol. 2003 Oct;16(10):1028-34. doi: 10.1097/01.MP.0000089777.58000.B2.
18	Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma.J Virol. 2009 May;83(9):4308-15. doi: 10.1128/JVI.02196-08. Epub 2009 Feb 18.
19	Overexpression of xCT induces up-regulation of 14-3-3beta in Kaposi's sarcoma.Biosci Rep. 2010 Mar 25;30(4):277-83. doi: 10.1042/BSR20090163.
20	Involvement of SSRP1 in latent replication of Kaposi's sarcoma-associated herpesvirus.J Virol. 2009 Nov;83(21):11051-63. doi: 10.1128/JVI.00907-09. Epub 2009 Aug 26.
21	Short-chain fatty acids from periodontal pathogens suppress histone deacetylases, EZH2, and SUV39H1 to promote Kaposi's sarcoma-associated herpesvirus replication.J Virol. 2014 Apr;88(8):4466-79. doi: 10.1128/JVI.03326-13. Epub 2014 Feb 5.
22	Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology.Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71. doi: 10.1006/bbrc.2000.2941.
23	Detection of viral DNA sequences in sporadic colorectal cancers in relation to CpG island methylation and methylator phenotype.Tumour Biol. 2011 Aug;32(4):653-9. doi: 10.1007/s13277-011-0165-6. Epub 2011 Apr 6.
24	Enhanced phosphorylation of sphingosine and ceramide sustains the exuberant proliferation of endothelial progenitors in Kaposi sarcoma.J Leukoc Biol. 2018 Mar;103(3):525-533. doi: 10.1002/JLB.2MA0817-312R. Epub 2017 Dec 15.
25	KSHV LANA upregulates the expression of epidermal growth factor like domain 7 to promote angiogenesis.Oncotarget. 2017 Dec 19;9(1):1210-1228. doi: 10.18632/oncotarget.23456. eCollection 2018 Jan 2.
26	EphA7 Functions as Receptor on BJAB Cells for Cell-to-Cell Transmission of the Kaposi's Sarcoma-Associated Herpesvirus and for Cell-Free Infection by the Related Rhesus Monkey Rhadinovirus.J Virol. 2019 Jul 17;93(15):e00064-19. doi: 10.1128/JVI.00064-19. Print 2019 Aug 1.
27	In vitro studies revealed a downregulation of Wnt/-catenin cascade by active vitamin D and TX 527 analog in a Kaposi's sarcoma cellular model.Toxicol In Vitro. 2020 Mar;63:104748. doi: 10.1016/j.tiv.2019.104748. Epub 2019 Dec 12.
28	Angiopoietin-2 is expressed in oral Kaposi's sarcoma.J Oral Pathol Med. 2017 Nov;46(10):1011-1014. doi: 10.1111/jop.12574. Epub 2017 Sep 8.
29	Angiopoietin-like 4: a novel molecular hallmark in oral Kaposi's sarcoma.Oral Oncol. 2011 May;47(5):371-5. doi: 10.1016/j.oraloncology.2011.02.018. Epub 2011 Mar 21.
30	KSHV vIRF4 enhances BCL6 transcription via downregulation of IRF4 expression.Biochem Biophys Res Commun. 2018 Feb 19;496(4):1128-1133. doi: 10.1016/j.bbrc.2018.01.154.
31	Model for the interaction of gammaherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex.J Virol. 2004 Aug;78(16):8673-86. doi: 10.1128/JVI.78.16.8673-8686.2004.
32	Kaposi's sarcoma virally encoded, G-protein-coupled receptor: a paradigm for paracrine transformation.Methods Enzymol. 2009;460:125-50. doi: 10.1016/S0076-6879(09)05206-9.
33	The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade.Blood. 2009 Jan 1;113(1):254-63. doi: 10.1182/blood-2008-02-140020. Epub 2008 Oct 3.
34	Insight into the Roles of E3 Ubiquitin Ligase c-Cbl, ESCRT Machinery, and Host Cell Signaling in Kaposi's Sarcoma-Associated Herpesvirus Entry and Trafficking.J Virol. 2018 Jan 30;92(4):e01376-17. doi: 10.1128/JVI.01376-17. Print 2018 Feb 15.
35	Cultured Kaposi's sarcoma cell lines express factor XIIIa, CD14, and VCAM-1, but not factor VIII or ELAM-1.Arch Dermatol. 1993 Oct;129(10):1291-6.
36	ID2-VEGF-related pathways in the pathogenesis of Kaposi's sarcoma: a link disrupted by rapamycin.Am J Transplant. 2009 Mar;9(3):558-66. doi: 10.1111/j.1600-6143.2008.02537.x.
37	The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor: Lessons on dysregulated angiogenesis from a viral oncogene.J Cell Biochem. 2010 May;110(1):1-9. doi: 10.1002/jcb.22524.
38	Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin 3 Levels and Is Dependent on STAT3.J Virol. 2020 Feb 14;94(5):e01384-19. doi: 10.1128/JVI.01384-19. Print 2020 Feb 14.
39	Deregulation of HDAC5 by Viral Interferon Regulatory Factor 3 Plays an Essential Role in Kaposi's Sarcoma-Associated Herpesvirus-Induced Lymphangiogenesis.mBio. 2018 Jan 16;9(1):e02217-17. doi: 10.1128/mBio.02217-17.
40	Cellular MicroRNA Let-7a Suppresses KSHV Replication through Targeting MAP4K4 Signaling Pathways.PLoS One. 2015 Jul 21;10(7):e0132148. doi: 10.1371/journal.pone.0132148. eCollection 2015.
41	Induction of interleukin-6 and oncostatin M by radiation in Kaposi's sarcoma cell lines.Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):533-40. doi: 10.1016/s0360-3016(01)01506-1.
42	NDRG1 facilitates the replication and persistence of Kaposi's sarcoma-associated herpesvirus by interacting with the DNA polymerase clamp PCNA.PLoS Pathog. 2019 Feb 27;15(2):e1007628. doi: 10.1371/journal.ppat.1007628. eCollection 2019 Feb.
43	Notch signal transduction induces a novel profile of Kaposi's sarcoma-associated herpesvirus gene expression.J Microbiol. 2006 Apr;44(2):217-25.
44	A herpesvirus transactivator and cellular POU proteins extensively regulate DNA binding of the host Notch signaling protein RBP-J to the virus genome.J Biol Chem. 2019 Aug 30;294(35):13073-13092. doi: 10.1074/jbc.RA118.007331. Epub 2019 Jul 15.
45	Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.Cancer Res. 2001 Mar 1;61(5):2183-8.
46	STAT6 degradation and ubiquitylated TRIML2 are essential for activation of human oncogenic herpesvirus.PLoS Pathog. 2018 Dec 10;14(12):e1007416. doi: 10.1371/journal.ppat.1007416. eCollection 2018 Dec.
47	Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.J Virol. 2015 Aug;89(15):7874-92. doi: 10.1128/JVI.00895-15. Epub 2015 May 20.
48	Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16541-16550. doi: 10.1073/pnas.1903991116. Epub 2019 Jul 25.
49	Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase.J Virol. 2018 Mar 14;92(7):e02003-17. doi: 10.1128/JVI.02003-17. Print 2018 Apr 1.
50	Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor.mBio. 2019 Feb 19;10(1):e02892-18. doi: 10.1128/mBio.02892-18.
51	Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study.Lancet HIV. 2018 Nov;5(11):e647-e655. doi: 10.1016/S2352-3018(18)30179-6. Epub 2018 Sep 21.
52	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.AIDS. 2018 Nov 28;32(18):2759-2765. doi: 10.1097/QAD.0000000000002004.
53	Major histocompatibility complex class I to III allotypes in patients with AIDS-related complex/Walter-Reed 5, disseminated Kaposi's sarcoma and in normal controls. The ARC-IVIG Study Group.Vox Sang. 1990;59 Suppl 1:15-20. doi: 10.1111/j.1423-0410.1990.tb01638.x.
54	ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.J Virol. 2016 Sep 29;90(20):9543-55. doi: 10.1128/JVI.03262-15. Print 2016 Oct 15.
55	KSHV strategies for host dsDNA sensing machinery.Virol Sin. 2016 Dec;31(6):466-471. doi: 10.1007/s12250-016-3877-3. Epub 2016 Dec 5.
56	Claudin-2 downregulation by KSHV infection is involved in the regulation of endothelial barrier function.J Cutan Pathol. 2014 Aug;41(8):630-9. doi: 10.1111/cup.12332. Epub 2014 Jul 4.
57	Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.J Virol. 2003 Jan;77(1):592-9. doi: 10.1128/jvi.77.1.592-599.2003.
58	A novel large deletion mutation of FERMT1 gene in a Chinese patient with Kindler syndrome.J Zhejiang Univ Sci B. 2015 Nov;16(11):957-62. doi: 10.1631/jzus.B1500080.
59	Fibroblast growth factor gene expression in AIDS-Kaposi's sarcoma detected by in situ hybridization.Am J Pathol. 1991 Jan;138(1):9-15.
60	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.Oncoimmunology. 2018 Dec 5;8(2):e1546544. doi: 10.1080/2162402X.2018.1546544. eCollection 2019.
61	ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.J Virol. 2005 Aug;79(16):10308-29. doi: 10.1128/JVI.79.16.10308-10329.2005.
62	Risk of Classic Kaposi Sarcoma With Combinations of Killer Immunoglobulin-Like Receptor and Human Leukocyte Antigen Loci: A Population-Based Case-control Study.J Infect Dis. 2016 Feb 1;213(3):432-8. doi: 10.1093/infdis/jiv413. Epub 2015 Aug 12.
63	Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.J Virol. 2003 Jan;77(1):600-23. doi: 10.1128/jvi.77.1.600-623.2003.
64	Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with human myeloid cell nuclear differentiation antigen induced by interferon alpha.Virus Genes. 2003 Dec;27(3):237-47. doi: 10.1023/a:1026391715071.
65	Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells.Chemotherapy. 2002 Dec;48(5):238-43. doi: 10.1159/000066765.
66	Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients.Arch Dermatol Res. 2011 Dec;303(10):763-9. doi: 10.1007/s00403-011-1161-9. Epub 2011 Jul 12.
67	Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.Hum Gene Ther. 2017 Mar;28(3):295-306. doi: 10.1089/hum.2016.108. Epub 2016 Dec 29.
68	Kaposi's Sarcoma-Associated Herpesvirus Nonstructural Membrane Protein pK15 Recruits the Class II Phosphatidylinositol 3-Kinase PI3K-C2 To Activate Productive Viral Replication.J Virol. 2018 Aug 16;92(17):e00544-18. doi: 10.1128/JVI.00544-18. Print 2018 Sep 1.
69	MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi's sarcoma cells.Oncotarget. 2016 Jun 14;7(24):36614-36621. doi: 10.18632/oncotarget.9311.
70	Lymph node-based disease and HHV-8/KSHV infection in HIV seronegative patients: report of three new cases of a heterogeneous group of diseases.Int J Hematol. 2011 Jun;93(6):795-801. doi: 10.1007/s12185-011-0849-0. Epub 2011 Apr 21.
71	Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency.PLoS Pathog. 2017 Apr 21;13(4):e1006335. doi: 10.1371/journal.ppat.1006335. eCollection 2017 Apr.
72	Multiple regions of Kaposi's sarcoma-associated herpesvirus ORF59 RNA are required for its expression mediated by viral ORF57 and cellular RBM15.Viruses. 2015 Feb 3;7(2):496-510. doi: 10.3390/v7020496.
73	Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLC1 and activating NFAT1-dependent RCAN1 expression.PLoS Pathog. 2012 Sep;8(9):e1002927. doi: 10.1371/journal.ppat.1002927. Epub 2012 Sep 27.
74	Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation.J Virol. 2009 Aug;83(16):8090-8. doi: 10.1128/JVI.02379-08. Epub 2009 Jun 3.
75	Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma.Proc Natl Acad Sci U S A. 2009 May 26;106(21):8683-8. doi: 10.1073/pnas.0812688106. Epub 2009 May 8.
76	Crystallographic and functional studies of a modified form of eosinophil-derived neurotoxin (EDN) with novel biological activities.J Mol Biol. 2002 Mar 15;317(1):119-30. doi: 10.1006/jmbi.2002.5406.
77	Kaposi's Sarcoma-Associated Herpesvirus ORF68 Is a DNA Binding Protein Required for Viral Genome Cleavage and Packaging.J Virol. 2018 Jul 31;92(16):e00840-18. doi: 10.1128/JVI.00840-18. Print 2018 Aug 15.
78	Mutation screening of SEMA3A and SEMA7A in patients with congenital hypogonadotropic hypogonadism.Pediatr Res. 2014 May;75(5):641-4. doi: 10.1038/pr.2014.23. Epub 2014 Feb 12.
79	SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.PLoS Pathog. 2017 Feb 17;13(2):e1006216. doi: 10.1371/journal.ppat.1006216. eCollection 2017 Feb.
80	Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling.J Virol. 2007 Mar;81(5):2401-17. doi: 10.1128/JVI.02024-06. Epub 2006 Dec 6.
81	Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter.J Virol. 1999 Feb;73(2):1438-46. doi: 10.1128/JVI.73.2.1438-1446.1999.
82	Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma.PLoS One. 2011 Apr 29;6(4):e19103. doi: 10.1371/journal.pone.0019103.
83	A20/TNFAIP3 inhibits NF-B activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein.Oncogene. 2013 Mar 7;32(10):1223-32. doi: 10.1038/onc.2012.145. Epub 2012 Apr 23.
84	Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis.J Clin Invest. 2019 Jul 15;129(8):3310-3323. doi: 10.1172/JCI127166. eCollection 2019 Jul 15.
85	KSHV RNA-binding protein ORF57 inhibits P-body formation to promote viral multiplication by interaction with Ago2 and GW182.Nucleic Acids Res. 2019 Sep 26;47(17):9368-9385. doi: 10.1093/nar/gkz683.
86	IFI16, a nuclear innate immune DNA sensor, mediates epigenetic silencing of herpesvirus genomes by its association with H3K9 methyltransferases SUV39H1 and GLP.Elife. 2019 Nov 4;8:e49500. doi: 10.7554/eLife.49500.
87	The interferon-stimulated gene product oligoadenylate synthetase-like protein enhances replication of Kaposi's sarcoma-associated herpesvirus (KSHV) and interacts with the KSHV ORF20 protein.PLoS Pathog. 2018 Mar 2;14(3):e1006937. doi: 10.1371/journal.ppat.1006937. eCollection 2018 Mar.
88	NCOA2 promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus by enhancing the expression of the master switch protein RTA.PLoS Pathog. 2019 Nov 21;15(11):e1008160. doi: 10.1371/journal.ppat.1008160. eCollection 2019 Nov.
89	kshv-mir-k12-1-5p promotes cell growth and metastasis by targeting SOCS6 in Kaposi's sarcoma cells.Cancer Manag Res. 2019 May 29;11:4985-4995. doi: 10.2147/CMAR.S198411. eCollection 2019.
90	Two herpesviral noncoding PAN RNAs are functionally homologous but do not associate with common chromatin loci.PLoS Pathog. 2018 Nov 1;14(11):e1007389. doi: 10.1371/journal.ppat.1007389. eCollection 2018 Nov.
91	Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life.Orphanet J Rare Dis. 2015 Jun 9;10:71. doi: 10.1186/s13023-015-0287-9.
92	Crystal structure of viral macrophage inflammatory protein I encoded by Kaposi's sarcoma-associated herpesvirus at 1.7A.J Mol Biol. 2005 Oct 7;352(5):1019-28. doi: 10.1016/j.jmb.2005.08.011.
93	HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism.PLoS Pathog. 2015 Feb 24;11(2):e1004652. doi: 10.1371/journal.ppat.1004652. eCollection 2015 Feb.
94	Complex Interactions between Cohesin and CTCF in Regulation of Kaposi's Sarcoma-Associated Herpesvirus Lytic Transcription.J Virol. 2020 Jan 6;94(2):e01279-19. doi: 10.1128/JVI.01279-19. Print 2020 Jan 6.
95	Kaposi's Sarcoma-Associated Herpesvirus ORF66 Is Essential for Late Gene Expression and Virus Production via Interaction with ORF34.J Virol. 2020 Jan 6;94(2):e01300-19. doi: 10.1128/JVI.01300-19. Print 2020 Jan 6.
96	Guanylate-Binding Protein 1 Inhibits Nuclear Delivery of Kaposi's Sarcoma-Associated Herpesvirus Virions by Disrupting Formation of Actin Filament.J Virol. 2017 Jul 27;91(16):e00632-17. doi: 10.1128/JVI.00632-17. Print 2017 Aug 15.
97	vFLIP upregulates IKK, leading to spindle morphology formation through RelA activation.Virology. 2018 Sep;522:106-121. doi: 10.1016/j.virol.2018.07.007. Epub 2018 Jul 17.
98	Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction.J Interferon Cytokine Res. 2011 Apr;31(4):373-82. doi: 10.1089/jir.2010.0084. Epub 2010 Dec 6.
99	Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3.J Virol. 2007 Aug;81(15):8282-92. doi: 10.1128/JVI.00235-07. Epub 2007 May 23.
100	The Kaposi's sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target.PLoS Pathog. 2017 Sep 22;13(9):e1006639. doi: 10.1371/journal.ppat.1006639. eCollection 2017 Sep.
101	Activation of Akt through gp130 receptor signaling is required for Kaposi's sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells.J Virol. 2008 Sep;82(17):8771-9. doi: 10.1128/JVI.00766-08. Epub 2008 Jun 25.
102	Chemokine receptors: interaction with HIV-1 and viral-encoded chemokines.Pharm Acta Helv. 2000 Mar;74(2-3):305-12. doi: 10.1016/s0031-6865(99)00040-0.
103	Two microPeptides are translated from a KSHV polycistronic RNA in human cells by leaky scanning mechanism.Biochem Biophys Res Commun. 2020 Feb 12;522(3):568-573. doi: 10.1016/j.bbrc.2019.11.087. Epub 2019 Nov 27.
104	The product of Kaposi's sarcoma-associated herpesvirus immediate early gene K4.2 regulates immunoglobulin secretion and calcium homeostasis by interacting with and inhibiting pERP1.J Virol. 2013 Nov;87(22):12069-79. doi: 10.1128/JVI.01900-13. Epub 2013 Aug 28.
105	Oroxylin A inhibits Kaposi's sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPAR/Prox1 axis.J Med Virol. 2019 Mar;91(3):463-472. doi: 10.1002/jmv.25337. Epub 2018 Nov 2.
106	Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression.PLoS One. 2007 Feb 28;2(2):e257. doi: 10.1371/journal.pone.0000257.
107	C19ORF66 Broadly Escapes Virus-Induced Endonuclease Cleavage and Restricts Kaposi's Sarcoma-Associated Herpesvirus.J Virol. 2019 May 29;93(12):e00373-19. doi: 10.1128/JVI.00373-19. Print 2019 Jun 15.
108	Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients.Virus Res. 2012 Feb;163(2):644-9. doi: 10.1016/j.virusres.2011.09.027. Epub 2011 Sep 22.
109	Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity.Nat Microbiol. 2019 Jan;4(1):164-176. doi: 10.1038/s41564-018-0285-5. Epub 2018 Nov 12.